Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Baylor College of Medicine Texas Children's Hospital The Methodist Hospital System |
---|---|
Information provided by: | Baylor College of Medicine |
ClinicalTrials.gov Identifier: | NCT00056979 |
This study treats patients with an inherited disease that prevents the body from making a specific protein or enzyme needed for the body's metabolism. Lack of this enzyme causes accumulation of harmful or toxic substances in the body, which leads to deterioration and failure of organs such as the brain or the heart. This disease can be fatal.
Some patients with inherited metabolic storage disease may benefit from an allogeneic stem cell transplant ('allogeneic' means that the stem cells come from another person). Stem cells are created in the bone marrow. They mature into different types of blood cells that are needed including red blood cells, white blood cells, and platelets. Stem cells, when transplanted, can make a new blood system. Donor stem cells can make the protein or enzyme patients with this disease cells cannot. The donor cells may prevent further accumulation of toxic substances. It is hoped that the donor cells can prevent or stop the disease from progressing.
This research study uses a new pre-treatment combination of two drugs, Anti-CD45 and CAMPATH-1H. Anti-CD45 and CAMPATH-1H are antibodies against certain types of blood cells. CAMPATH-1H is particularly important because it stays active in the body for a long time after infusion, which means it may work longer at preventing GVHD symptoms. In addition to antibodies, patients will receive Fludarabine, which is a chemotherapy drug. Fludarabine kills bone marrow cells and is given to reduce the bone marrow cells so that donor stem cells may 'take.'
Condition | Intervention | Phase |
---|---|---|
Inherited Metabolic Storage Diseases |
Drug: CAMPATH-1H Drug: Anti-CD45 Drug: FK506 Drug: Fludarabine |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Anti-CD45 (YTH-24 & YTH 54) and ANTI-CD52 (CAMPATH-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases |
Estimated Enrollment: | 27 |
Study Start Date: | June 2002 |
Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) infusion for three days. Anti-CD45 will be given as a daily 6-hour IV infusion over the next 4 days. Then patients will have a one-day rest period before receiving the stem cell transplant. To help prevent the body from rejecting the transplant, patients will also receive the drug FK506, starting two days before the transplant and continuing for three months. If there is no GVHD, the amount of FK506 patients are taking will be reduced by 20% every 2 weeks until this medication is stopped.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
United States, Texas | |
The Methodist Hospital | |
Houston, Texas, United States | |
Texas Children's Hospital | |
Houston, Texas, United States |
Study Chair: | Malcolm K Brenner, MD | Baylor College of Medicine |
Study ID Numbers: | H11909, MAID |
Study First Received: | March 26, 2003 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00056979 |
Health Authority: | United States: Food and Drug Administration |
Metabolic diseases |
Antibodies, Monoclonal Antibodies Metabolic Diseases Alemtuzumab Tacrolimus |
Fludarabine Fludarabine monophosphate Metabolic disorder Immunoglobulins |
Immunologic Factors Antineoplastic Agents Therapeutic Uses Physiological Effects of Drugs Pharmacologic Actions |